Emerging therapeutic platforms
Emerging field of therapeutics, cell, and gene therapies can be impactful in diseases currently deemed untreatable. Opportunities include discovery and development of new drug candidates, platform services to support R&D and manufacturing, as well as the manufacturing and supply chain infrastructure to support large scale production of these treatments.
Our approach
Our approach is rooted in a deep understanding of the healthcare industry and a commitment to making a positive impact. We are currently focused on investing in companies that:
Significantly enhance patient outcomes
We support companies that are dedicated to advancing research and development in healthcare, paving the way for development of new healthcare products, treatments, therapies and cures.
Involve a substantial ‘Make-in-India’ component
We seek out companies which are focused on manufacturing top-notch healthcare products for domestic as well as global markets.
Harness technology to augment healthcare delivery
We intend to invest in companies that utilize advanced technologies like artificial intelligence, machine learning and data analytics to improve efficiency of healthcare delivery and outcome. In particular, we are keen on digital health concepts which focus on developing therapeutic ideas, analyzing medical data, and identifying patterns.
Related partnerships
Perspectives
What we’re reading.
Perspectives
Superfluid Dx - Leveraging cf-mRNA for early disease detection
Superfluid Dx - Leveraging cf-mRNA for early disease detection
Perspectives
Investing in BillionToOne – Amplifying the power of molecular diagnostics
Investing in BillionToOne – Amplifying the power of molecular diagnostics
Perspectives
Enveda | Efficient drug development, naturally
November 26, 2024
Enveda | Efficient drug development, naturally
Perspectives
Announces Substantial Expansion of Research Campus
January 10, 2024
Adimab
Announces Substantial Expansion of Research Campus
Perspectives
Provides Year-End Update on 2023 Partnership Activities
January 8, 2024
Adimab
Provides Year-End Update on 2023 Partnership Activities
Perspectives
Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 1, 2024
Bicara Therapeutics
Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Perspectives
MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST
April 17, 2024
Billion to One
MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST
Perspectives
Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials
November 13, 2024
Business Wire
Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials
Perspectives
WRQ Sciences and Superfluid Dx., Inc. Announce Completion of Oversubscribed Series A Financing in Breakthrough Alzheimer's Disease Diagnostic Company Superfluid Dx
December 20, 2023
PR Newswire
